|
1
|
Livraghi T, Mäkisalo H and Line PD:
Treatment options in hepatocellular carcinoma today. Scand J Surg.
100:22–29. 2011.PubMed/NCBI
|
|
2
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Lope CR, Tremosini S, Forner A, et al:
Management of HCC. J Hepatol. 56(Suppl 1): S75–S87. 2012.
|
|
4
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Umemura T and Kiyosawa K: Epidemiology of
hepatocellular carcinoma in Japan. Hepatol Res. 37(Suppl 2):
S95–S100. 2007. View Article : Google Scholar
|
|
6
|
Nishikawa H, Osaki Y, Kita R, et al:
Transcatheter arterial infusion chemotherapy prior to
radiofrequency thermal ablation for single hepatocellular carcinoma
reduces the risk of intrahepatic distant recurrence. Int J Oncol.
41:903–909. 2012.
|
|
7
|
Zhou WP, Lai EC, Li AJ, et al: A
prospective, randomized, controlled trial of preoperative
transarterial chemoembolization for resectable large hepatocellular
carcinoma. Ann Surg. 249:195–202. 2009. View Article : Google Scholar
|
|
8
|
Ohki T, Tateishi R, Goto E, et al:
Influence of anti-HBc seropositivity on the risk of hepatocellular
carcinoma in HCV-infected patients after adjusting for confounding
factors. J Viral Hepat. 17:91–97. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Squadrito G, Pollicino T, Cacciola I, et
al: Occult hepatitis B virus infection is associated with the
development of hepatocellular carcinoma in chronic hepatitis C
patients. Cancer. 106:1326–1330. 2006. View Article : Google Scholar
|
|
10
|
Ikeda K, Marusawa H, Osaki Y, et al:
Antibody to hepatitis B core antigen and risk for hepatitis
C-related hepatocellular carcinoma: a prospective study. Ann Intern
Med. 146:649–656. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lok AS, Everhart JE and Di Bisceglie AM;
HALT-C Trial Group. Occult and previous hepatitis B virus infection
are not associated with hepatocellular carcinoma in United States
patients with chronic hepatitis C. Hepatology. 54:434–442. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marusawa H, Osaki Y, Kimura T, et al: High
prevalence of anti-hepatitis B virus serological markers in
patients with hepatitis C virus related chronic liver disease in
Japan. Gut. 45:284–288. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shiota G, Oyama K, Udagawa A, et al:
Occult hepatitis B virus infection in HBs antigen-negative
hepatocellular carcinoma in a Japanese population: involvement of
HBx and p53. J Med Virol. 62:151–158. 2000. View Article : Google Scholar
|
|
14
|
Jilg W, Sieger E, Zachoval R and Schätzl
H: Individuals with antibodies against hepatitis B core antigen as
the only serological marker for hepatitis B infection: high
percentage of carriers of hepatitis B and C virus. J Hepatol.
23:14–20. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cacciola I, Pollicino T, Squadrito G,
Cerenzia G, Orlando ME and Raimondo G: Occult hepatitis B virus
infection in patients with chronic hepatitis C liver disease. N
Engl J Med. 341:22–26. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tanaka K, Nagao Y, Ide T, Kumashiro R and
Sata M: Antibody to hepatitis B core antigen is associated with the
development of hepatocellular carcinoma in hepatitis C
virus-infected persons: a 12-year prospective study. Int J Mol Med.
17:827–832. 2006.
|
|
17
|
Bruix J and Sherman M: Practice Guidelines
Committee, American Association for the Study of Liver Diseases:
Management of hepatocellular carcinoma. Hepatology. 42:1208–1236.
2005. View Article : Google Scholar
|
|
18
|
Liver Cancer Study Group of Japan. The
general rules for the clinical and pathological study of primary
liver cancer. Jpn J Surg. 19:98–129. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marusawa H, Uemoto S, Hijikata M, et al:
Latent hepatitis B virus infection in healthy individuals with
antibodies to hepatitis B core antigen. Hepatology. 31:488–495.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
National Institutes of Health. Consensus
Development Conference Statement. Management of hepatitis C: June
10–12, 2002. Hepatology. 36(Suppl 1): S3–S20. 2002.
|
|
21
|
Strader DB, Wright T, Thomas DL and Seeff
LB; American Association for the Study of Liver Diseases.
Diagnosis, management, and treatment of hepatitis C. Hepatology.
39:1147–1171. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mazzaferro V, Romito R and Schiavo M; HCC
Italian Task Force. Prevention of hepatocellular carcinoma
recurrence with alpha-interferon after liver resection in HCV
cirrhosis. Hepatology. 44:1543–1554. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lim KC, Chow PK, Allen JC, et al:
Microvascular invasion is a better predictor of tumor recurrence
and overall survival following surgical resection for
hepatocellular carcinoma compared to the Milan criteria. Ann Surg.
254:108–113. 2011. View Article : Google Scholar
|
|
24
|
Sakae M, Kubo S, Takemura S, et al: Effect
of interferon therapy on first and second recurrence after
resection of hepatitis C virus-related hepatocellular carcinoma.
Hepatol Res. 42:564–573. 2012. View Article : Google Scholar
|
|
25
|
Tanimoto Y, Tashiro H, Aikata H, et al:
Impact of pegylated interferon therapy on outcomes of patients with
hepatitis C virus-related hepatocellular carcinoma after curative
hepatic resection. Ann Surg Oncol. 19:418–425. 2012. View Article : Google Scholar
|
|
26
|
Singal AK, Freeman DH Jr and Anand BS:
Meta-analysis: interferon improves outcomes following ablation or
resection of hepatocellular carcinoma. Aliment Pharmacol Ther.
32:851–858. 2010. View Article : Google Scholar
|
|
27
|
Lautz HU, Selberg O, Körber J, Bürger M
and Müller MJ: Protein-calorie malnutrition in liver cirrhosis.
Clin Investig. 70:478–486. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Italian Multicentre Cooperative Project on
Nutrition in Liver Cirrhosis. Nutritional status in cirrhosis. J
Hepatology. 21:317–335. 1994. View Article : Google Scholar
|
|
29
|
Nishikawa H, Osaki Y, Inuzuka T, et al:
Branched-chain amino acid treatment before transcatheter arterial
chemoembolization for hepatocellular carcinoma. World J
Gastroenterol. 18:1379–1384. 2012. View Article : Google Scholar
|
|
30
|
Nishikawa H, Osaki Y, Iguchi E, et al: The
effect of long-term supplementation with branched-chain amino acid
granules in patients with hepatitis C virus-related hepatocellular
carcinoma after radiofrequency thermal ablation. J Clin
Gastroenterol. 47:359–366. 2012. View Article : Google Scholar
|
